Trial Profile

A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 25 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mirikizumab (Primary)
Indications Ulcerative colitis
Focus Registrational; Therapeutic Use
Acronyms LUCENT 3
Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd; Eli Lilly Japan

Most Recent Events

06 Dec 2024 Planned End Date changed from 20 Dec 2027 to 1 Dec 2027.
06 Dec 2024 Planned primary completion date changed from 7 Jul 2026 to 1 Jul 2026.
05 Dec 2024 Results from the LUCENT-3 open-label extension study published in the Inflammatory Bowel Diseases.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com